Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - prilocaine hydrochloride, quantity: 5 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - indications as at 12 march 1996: citanest solutions are indicated for the production of local or regional anaesthesia by infiltration techniques; intravenous regional anaesthesia; by peripheral nerve block techniques such as intercostal blocks; major plexus blocks such as brachial plexus blocks and by epidural and subarachnoid blocks.

Australia - English - Department of Health (Therapeutic Goods Administration)

dentsply sirona pty ltd - prilocaine hydrochloride, quantity: 30 mg/ml; felypressin, quantity: 0.03 iu/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide; sodium acetate; chlorobutanol hemihydrate; acetic acid - indications as at 23 july 2003 : citanest is indicated for the production of local anaesthesia in routine dental procedures and oral surgery by means of infiltration and nerve block tecniques.

United States - English - NLM (National Library of Medicine)

dentsply pharmaceutical inc. - prilocaine hydrochloride (unii: mjw015baph) (prilocaine - unii:046o35d44r), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - citanest forte is indicated for the production of local anesthesia in dentistry by nerve block or infiltration techniques. only accepted procedures for these techniques as described in standard textbooks are recommended. prilocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type and in those rare patients with congenital or idiopathic methemoglobinemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

dentsply sirona pty ltd - prilocaine hydrochloride, quantity: 40 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - indications as at 23 july 2003 : citanest is indicated for the production of local anaesthesia in routine dental procedures and oral surgery by means of infiltration and nerve block techniques.

Australia - English - Department of Health (Therapeutic Goods Administration)

dentsply sirona pty ltd - prilocaine hydrochloride, quantity: 30 mg/ml; adrenaline (epinephrine) acid tartrate, quantity: 0.0061 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium metabisulfite; water for injections; hydrochloric acid; sodium hydroxide - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) indications as at 14 july 2003 : citanest is indicated for the production of local anaesthesia in routine dental procedures and oral surgery by means of infiltration and nerve block techniques.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - adrenaline acid tartrate; prilocaine hydrochloride; adrenaline -

Australia - English - Department of Health (Therapeutic Goods Administration)

dentsply sirona pty ltd - prilocaine hydrochloride, quantity: 30 mg/ml; felypressin, quantity: 0.54 microgram/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - citanest is indicated for the production of local anaesthesia in routine dental procedures and oral surgery by means of infiltration and nerve block techniques.

United States - English - NLM (National Library of Medicine)

dentsply pharmaceutical inc. - prilocaine hydrochloride (unii: mjw015baph) (prilocaine - unii:046o35d44r), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - prilocaine hydrochloride 40 mg in 1 ml - 4% citanest plain dental (prilocaine hcl) and 4% citanest forte dental injections are indicated for the production of local anesthesia in dentistry by nerve block or infiltration techniques. only accepted procedures for these techniques as described in standard textbooks are recommended. prilocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type and in those rare patients with congenital or idiopathic methemoglobinemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - prilocaine hydrochloride, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; water for injections - citanest solutions are indicated for the production of local or regional anaesthesia by infiltration techniques; intravenous regional anesthesia; by peripheral nerve block techniques such as intercostal blocks; major plexus blocks such as brachial plexus blocks and by epidural and subarachnoid blocks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - prilocaine hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride - citanest solutions are indicated for the production of local or regional anaesthesia by infiltration techniques; intravenous regional anaesthesia; by peripheral nerve block techniques such as intercostal blocks; major plexus blocks such as brachial plexus blocks and by epidural and subarachnoid blocks.